Fig. 3
From: Chimeric antigen receptor T cell therapy for multiple myeloma
![Fig. 3](http://media.springernature.com/full/springer-static/image/art%3A10.1186%2Fs41232-019-0100-6/MediaObjects/41232_2019_100_Fig3_HTML.png)
MMG49 CAR T cell provides the first clear evidence that a receptor protein with a rare but physiologically relevant conformation could serve as a target for cancer immunotherapy